Nov 21, 2019 · Here, we discuss physiologic and pathogenic function of EZH2 in lymphoid context, various internal causes of EZH2 aberrance and how EZH2 modulates lymphomagenesis through epigenetic silencing, post-translational modifications (PTMs), orchestrating with surrounding tumor micro-environment and associating with RNA or viral partners.

Oct 10, 2012 · Here we demonstrate that GSK126, a potent, highly selective, S -adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and...

EZH2 mutations initiate lymphomagenesis by reprogramming the GC microenvironment. EZH2 mutation attenuates B cell requirement for T cell help. Mutant EZH2 drives expansion of GC centrocytes that are dependent on FDCs. Mutant EZH2 establishes the characteristic follicular lymphoma immunological niche. ACKNOWLEDGEMENTS

Nov 5, 2024 · We hypothesize that EZH2 Y641F/+ and EZH2 OE are non-equivalent gain-of-function events that drive lymphoma by distinct mechanisms. We have established two separate and tissue-specific mouse models of EZH2 Y641F/+ and EZH2 OE …

Dec 5, 2024 · This manuscript presents evidence that inhibiting EZH2 can overcome CAR-T therapy resistance by enhancing lymphoma immunogenicity, facilitating interaction between lymphoma B cells and T cells, and improving endogenous T cell and CAR-T cell functions.

EZH2 is mutated in nearly 25% of follicular lymphoma (FL) cases. Little is known about how EZH2 affects patients’ response to therapy.

Mar 11, 2025 · Lymphoma, a malignant tumor derived from lymphocytes and lymphoid tissues, presents with complex and heterogeneous clinical manifestations, requiring accurate patient classification for appropriate treatment. ... Follicular lymphoma and marginal zone lymphoma. EZH2 is an important biomarker for guiding frontline treatment in FL, with ...

Here, we critically review the emerging role of EZH2 in malignancies, the development of small molecule inhibitors of EZH2, and their application in lymphoma. Recent findings: Activating mutations and overexpression of EZH2 are found in non-Hodgkin lymphoma (NHL).

Oct 31, 2013 · EZH2 mutations occur in more than 25% of follicular lymphoma patients. Mutations predominantly represent an early/clonal event in the pathogenesis of the disease. Gain of function mutations in the H3K27 methyltransferase EZH2 represent a promising therapeutic target in germinal center lymphomas.

4 days ago · Notably, EZH2 is catalytically inactive and requires association with EED and SUZ12 to form an active PRC2 complex. Hyperactivation of EZH2 has been implicated in various malignancies, prompting the development of EZH2 inhibitors as therapeutic agents for several cancers, including lymphoma, prostate, breast, and colon cancer.